DermTech, Inc.
DMTK · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.45 | 0.01 | 0.66 |
| FCF Yield | -71.42% | -20.88% | -39.19% | -28.38% |
| EV / EBITDA | -2.62 | -4.58 | -3.61 | -3.10 |
| Quality | ||||
| ROIC | -20.51% | -17.70% | -15.45% | -22.41% |
| Gross Margin | 18.54% | 11.21% | 4.39% | 0.20% |
| Cash Conversion Ratio | 0.86 | 0.67 | 0.99 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.32% | 8.92% | 10.00% | 15.40% |
| Free Cash Flow Growth | -36.47% | 34.30% | 18.62% | -2.96% |
| Safety | ||||
| Net Debt / EBITDA | -1.37 | -1.04 | -0.97 | -0.41 |
| Interest Coverage | 0.00 | -25.49 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.77 | 3.47 | 3.13 | 2.94 |
| Cash Conversion Cycle | 27.36 | 46.87 | 70.68 | 65.38 |